Westwood Holdings Group Inc. Has $8.57 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westwood Holdings Group Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 12,024 shares of the biopharmaceutical company’s stock after selling 90 shares during the period. Westwood Holdings Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,565,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Merit Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.9% during the fourth quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 71 shares during the last quarter. HB Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.2% during the fourth quarter. HB Wealth Management LLC now owns 2,129 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 161 shares during the last quarter. Diversify Advisory Services LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $234,000. Mechanics Bank Trust Department purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $288,000. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 92 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. StockNews.com lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Finally, Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $890.60.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $614.79 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business’s 50-day simple moving average is $596.79 and its two-hundred day simple moving average is $679.72. The stock has a market cap of $66.38 billion, a PE ratio of 16.06, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $9.55 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.57%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.